Tocilizumab-bavi (Tofidence) will offer a lower-cost option for patients with autoimmune conditions, the drug manufacturer, Biogen, stated.
biosimilar approved by the FDA. The reference product, Actemra , was first approved by the agency in 2010.
"The approval of Tofidence in the U.S. marks another positive step toward helping more people with chronic autoimmune conditions gain access to leading therapies," said Ian Henshaw, global head of biosimilars at Biogen, in a statement."With the increasing numbers of approved biosimilars, we expect increased savings and sustainability for healthcare systems and an increase in physician choice and patient access to biologics.
Tocilizumab-bavi is an intravenous formulation indicated for treatment of moderately to severely active
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Exxua for major depressive disorder treatmentThe drug company announced that Exxua is the first authorized antidepressant for MDD.
Read more »
First FDA approved drug to slow Alzheimer’sMore than six million Americans are living with Alzheimer’s disease – it slowly steals your memories and takes away your mind. There is no cure, yet, but now, a newly FDA-approved drug is helping to slow its progression before it’s too late.
Read more »
Spring Branch ISD board approves to lower tax rate nearly 19 cents lower than 2022Homeowners in Spring Branch Independent School District will see a $0.1889 reduction in their district tax rate from last year, according to a release.
Read more »
First Killers Of The Flower Moon Clip Sees Leonardo DiCaprio & Lily Gladstone's First MeetingKillers of the Flower Moon arrives October 20.
Read more »
Everything to Know About First Impression Rose Winner Faith MartinGolden Bachelor Gerry Turner handed out the show's first-ever First Impression Rose on Thursday.
Read more »
FDA panel overwhelmingly votes against experimental ALS treatment pushed by patientsFederal health advisors voted 17-1 against an experimental treatment for Lou Gehrig's disease dubbed NurOwn, although the FDA is not bound by the vote.
Read more »